Arcadia Biosciences CEO Thomas Schaefer buys $1,743 in stock

Published 06/02/2025, 01:26
Arcadia Biosciences CEO Thomas Schaefer buys $1,743 in stock

Arcadia Biosciences , Inc. (NASDAQ:RKDA) Chief Executive Officer Thomas J. Schaefer recently acquired 700 shares of the company’s common stock. The stock, currently trading at $4.80, has shown remarkable momentum with an 85% gain over the past six months, according to InvestingPro data. This purchase, made on February 3, 2025, was valued at approximately $1,743, with each share priced at $2.49. The acquisition was conducted under the company’s 2015 Employee Stock Purchase Plan, which allows employees to buy shares at a discount. Following this transaction, Schaefer holds a total of 2,819 shares in the company. While the company maintains strong liquidity with a current ratio of 4.6 and holds more cash than debt, InvestingPro analysis suggests the stock is currently undervalued, with 12 additional key insights available to subscribers.

In other recent news, Arcadia Biosciences reported an 18% year-over-year increase in third-quarter revenues, reaching approximately $1.5 million. This growth was primarily fueled by a 55% surge in sales of Zola Coconut Water, which now accounts for 86% of total revenues. The company’s financial health showed signs of improvement with a decrease in cash usage to $1.5 million, the lowest since the company went public.

Despite facing some challenges, including a $150,000 write-down related to its legacy businesses, Arcadia has seen positive developments. The company’s gross margins are expected to stabilize around 33%, and Zola’s retail distribution grew by 68% year-over-year. Moreover, Arcadia is preparing for a new product launch in the 2025 beverage season.

However, the company faced a decrease in cash and short-term investments, down from $8.1 million in Q2 to $6.6 million. Severance and transition costs following the sale of GoodWheat also contributed to a rise in expenses. Despite these challenges, these are recent developments in Arcadia Biosciences’ ongoing journey.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.